Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma

I G Schmidt-Wolf, S Finke, B Trojaneck, A Denkena, P Lefterova, N Schwella, H G Heuft, G Prange, M Korte, M Takeya, T Dorbic, A Neubauer, B Wittig, D Huhn, I G Schmidt-Wolf, S Finke, B Trojaneck, A Denkena, P Lefterova, N Schwella, H G Heuft, G Prange, M Korte, M Takeya, T Dorbic, A Neubauer, B Wittig, D Huhn

Abstract

Natural killer-like T lymphocytes termed cytokine-induced killer (CIK) cells have been shown to eradicate established tumours in a severe combined immune deficient (SCID) mouse/human lymphoma model. Recently, we demonstrated that CIK cells transfected with cytokine genes possess an improved proliferation rate and a significantly higher cytotoxic activity as compared to non-transfected cells. Here, in a phase I clinical protocol, autologous CIK cells were generated from peripheral blood obtained by leukapheresis in patients with metastatic renal cell carcinoma, colorectal carcinoma and lymphoma. CIK cells were transfected with a plasmid containing the interleukin-2 (IL-2) gene via electroporation. Transfected cells generated IL-2 in the range of 330-1800 pg 10(-6) cells 24 h(-1) with a mean of 836 pg 10(-6) cells 24 h(-1). Ten patients received 1-5 intravenous infusions of IL-2-transfected CIK cells; five infusions with transfected CIK cells were given. In addition, the same patients received five infusions with untransfected CIK cells for control reasons. In three patients, WHO grade 2 fever was observed. Based on polymerase chain reaction of peripheral blood transfected cells could be detected for up to 2 weeks after infusion. There was a significant increase in serum levels of interferon gamma (IFN-gamma), granulocyte-macrophage colony-stimulating factor (GM-CSF) and transforming growth factor beta (TGF-beta) during treatment. Interestingly, there was also an increase in CD3+ lymphocytes in the blood of patients during therapy. In accordance, a partial increase in cytotoxic activity in peripheral blood lymphocytes (PBLs) was documented when patient samples before and after therapy were compared. Concerning clinical outcome, six patients remained in progressive disease, three patients showed no change by treatment, and one patient with lymphoma developed a complete response. In conclusion, we were able to demonstrate that CIK cells transfected with the IL-2 gene can be administered without major side-effects and are promising for future therapeutic trials.

References

    1. Cancer Res. 1981 Nov;41(11 Pt 1):4420-5
    1. J Exp Med. 1982 Jun 1;155(6):1823-41
    1. Science. 1986 Sep 19;233(4770):1318-21
    1. J Immunol. 1989 Dec 1;143(11):3562-7
    1. N Engl J Med. 1990 Aug 30;323(9):570-8
    1. J Immunol. 1990 Sep 15;145(6):1983-90
    1. J Immunol. 1990 Oct 15;145(8):2415-20
    1. J Exp Med. 1991 Jul 1;174(1):139-49
    1. J Immunol. 1993 May 1;150(9):4104-15
    1. J Immunol. 1994 Aug 15;153(4):1687-96
    1. Br J Haematol. 1994 Jul;87(3):453-8
    1. Hum Gene Ther. 1994 Sep;5(9):1161-8
    1. Blood. 1995 Nov 1;86(9):3493-9
    1. Hum Gene Ther. 1995 Jun;6(6):753-61
    1. Histol Histopathol. 1996 Apr;11(2):521-36
    1. Cytokine Growth Factor Rev. 1996 Jun;7(1):93-102
    1. Ann Hematol. 1996 Nov;73(5):207-18
    1. J Immunol. 1997 Feb 15;158(4):1591-7
    1. Ann Hematol. 1997 Feb;74(2):51-6
    1. Lab Invest. 1997 May;76(5):739-49
    1. Gene Ther. 1997 Apr;4(4):296-302
    1. Immunol Rev. 1997 Jun;157:231-40
    1. Gene Ther. 1998 Jan;5(1):31-9
    1. Cancer Immunol Immunother. 1998 Dec;47(4):221-6

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe